Inspire Medical Systems, Inc. Profit Rises In Q4

Inspire Medical Systems reported a blowout Q4 with GAAP earnings of $136.09 million ($4.66 EPS) versus $35.22 million ($1.15) a year ago, and adjusted earnings of $48.10 million ($1.65 EPS). Revenue climbed 12.2% to $269.07 million from $239.71 million the prior year. Management provided FY2026 adjusted net income per diluted share guidance of $1.85–$2.35 and revenue guidance of $950 million–$1.0 billion, signaling continued top-line growth and strong profitability momentum that could act as a near-term positive catalyst for the stock.

Analysis

Market structure: Strong Q4 revenue (+12.2% y/y to $269M) and outsized GAAP EPS (driven by one-offs; adjusted Q4 EPS $1.65) suggest positive demand for Inspire’s implantable sleep-apnea therapy and growing pricing power in procedure-based devices. Winners include INSP (market share gains vs CPAP incumbents where patients fail therapy) and hospital/surgical-capex vendors; losers could be CPAP-focused names if diversion accelerates. Expect short-term risk-on flows into mid-cap med-tech, modest downward pressure on high-grade sovereign bonds as investors rotate into equities.

Risk assessment: Tail risks include an adverse FDA safety signal, major reimbursement cuts (Medicare/insurer policy revision), or supply-chain hiccups that could wipe out the narrow margin between GAAP and adjusted profits; each is low probability but could halve market cap. Immediate (days) — earnings volatility and vol compression; short-term (weeks/months) — guidance re-pricing around FY2026 adjusted EPS $1.85–$2.35 and revenue $950M–$1.0B; long-term (quarters/years) — adoption, international approvals and reimbursement determine sustainable growth. Hidden dependency: procedure volume hinges on physician training and hospital OR capacity, not just patient demand.

Trade implications: Direct equity exposure to INSP is warranted but size-constrained: convex upside if procedure adoption continues; prefer staged buys on 8–12% pullbacks. Pair trade: long INSP vs short RMD (ResMed) to express share-shift from CPAP to implants over 6–12 months. Options: use 3–6 month call spreads (buy ~25–35 delta, sell strike ~15–25% higher) to limit premium decay, and buy short-dated puts (10–15% OTM) as regulatory insurance.

Contrarian angles: The market may be underweight that Q4 GAAP spike was one-time — consensus could over-rotate, leaving disappointment if FY blended EPS backs into the $1.85–$2.35 range. Historical parallels: device winners that showed strong quarter but constrained adoption (e.g., early-stage implantables) often trade sideways for 6–12 months until reimbursement/physician uptake proves out. Overdone reaction risk: if investors ignore procedural bottlenecks, near-term multiple expansion could revert sharply on any guidance softness.

Key Decisions for Investors

• Establish a staged long position in INSP equal to 2–3% of portfolio capital over 1–3 weeks, adding on intraday pullbacks of 8–12%; target 30–40% upside in 12 months, hard stop-loss at 20% below entry.
• Implement a relative-value pair: long INSP (2% of portfolio) and short RMD (ResMed) at 1.5% notional to hedge macro/sector moves; horizon 6–12 months, close if spread moves >25% adverse or converges by 10%.
• Buy a 3–6 month call spread on INSP sized to 1–1.5% portfolio risk: purchase ~25–35 delta calls and sell calls ~15–25% higher to cap cost, aiming to capture upside if adoption accelerates post-earnings.
• Purchase 3-month 10–15% OTM puts sized to 0.5% portfolio as regulatory/reimbursement insurance; sell these if no negative headlines within 90 days or if implied volatility compresses >30%.
• Reallocate 1–2% from broader healthcare ETFs into select med-tech (device) names over 3 months, underweight CPAP incumbents, and review Medicare/reimbursement policy updates on a 30–60 day cadence before adding further exposure.